id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
cord-281285-5g1rw202	Simonis, Alexander	A comparative analysis of remdesivir and other repurposed antivirals against SARS‐CoV‐2	2020-11-03		.txt	text/plain	9501	504	46	Based on its MOA, repurposed drugs with anti-SARS-CoV-2 activity can be divided into substances that prevent viral entry into host cells (1-2) and inhibit viral proteases (3) and inhibitors of viral replicase (4). The disappointing clinical results might be related to sub-therapeutic levels for inhibition of SARS-COV-2 because application of 400/100 mg of lopinavir/ritonavir twice daily was shown to yield median serum concentrations of 7.2 mg/l (11.5 µM) in patients with HIV (van der Lugt et al, 2009), which is significantly lower than the observed EC 50 in the in vitro studies. In this comparative review, we focus on repurposed drugs with antiviral effects against SARS-CoV-2 in cell-based assays as those substances offer great opportunities for a treatment early in the course of COVID-19 by inhibition of viral replication and might be even suitable for preventive strategies as shown for neuraminidase inhibitors in case of influenza (Jefferson et al, 2014) .	./cache/cord-281285-5g1rw202.txt	./txt/cord-281285-5g1rw202.txt